Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03295877 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03295877 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 28 participants.
The verdict
NCT03295877, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD. The study consists of two stages: Single Dose-Escalation (SAD) and Multiple-Dose (MD) stages.
Interventions
- DRUG RO7171009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2018-11-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03295877
The ClinicalTrials.gov registry entry for NCT03295877 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RO7171009 is the first listed.
NCT03295877 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03295877 about?
NCT03295877 is a clinical study titled "Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)". This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD. The study consists of two stages: Single Dose-Escalation (SAD) and Multiple-Dose (MD) stages.
What is the current status of trial NCT03295877?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2017-09-21. Estimated completion is 2018-11-20.
What interventions are being tested in trial NCT03295877?
The interventions under investigation include: RO7171009 (DRUG).
Who is sponsoring clinical trial NCT03295877?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.